Roche Signs Up Ipsen--Again
Roche's October 2003 in-licensing of Ipsen's Phase I GLP-1 analog buys the Swiss group an initial stake in the fast-growing diabetes market. Most established diabetes players already have a compound in this class, but the partners hope that Ipsen's expertise in peptide delivery will set this program apart from competitors'. As the second licensing agreement between Roche and Ipsen in less than a year, the deal further validates Ipsen's pipeline, and suggests that Roche's carefully-managed partnership strategy continues to encourage repeat business.
You may also be interested in...
Novo Nordisk is confident that it can continue to generate strong growth from its leading diabetes franchise. Having exited oral anti-diabetics, it's betting on further innovation in insulin and on a strong entry into the GLP-1 analog space.
Europe's financing environment makes it difficult to build big biotech from scratch. But sustainable biopharma firms are nevertheless emerging--mostly through the transformation of existing pharma assets.
Denmark's Gastrotech Pharma is harnessing gastro-intestinal hormones such as ghrelin and GLP-1 to develop more effective therapies for irritable bowel syndrome and cachexia.